Cargando…

Concurrent Chemoradiotherapy without Brachytherapy in Locally Advanced Cervical Cancer

BACKGROUND: Concurrent chemoradiotherapy (EBRT + cisplatin) plus intracavitary brachytherapy is the standard of care in patients with advanced cervical cancer. However, a number of patients could not undergone brachytherapy due to massive residual tumor or anatomical distortion. In this study, we ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Kadkhodayan, Sima, Homaei Shandiz, Fatemeh, Seilanian Toussi, Mehdi, Afzal Aghaee, Monavar, Farshidi, Farnoosh, Dehghan, Parvane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Research Center, Shahid Beheshti University of Medical Sciences 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4142937/
https://www.ncbi.nlm.nih.gov/pubmed/25250134
_version_ 1782331838714347520
author Kadkhodayan, Sima
Homaei Shandiz, Fatemeh
Seilanian Toussi, Mehdi
Afzal Aghaee, Monavar
Farshidi, Farnoosh
Dehghan, Parvane
author_facet Kadkhodayan, Sima
Homaei Shandiz, Fatemeh
Seilanian Toussi, Mehdi
Afzal Aghaee, Monavar
Farshidi, Farnoosh
Dehghan, Parvane
author_sort Kadkhodayan, Sima
collection PubMed
description BACKGROUND: Concurrent chemoradiotherapy (EBRT + cisplatin) plus intracavitary brachytherapy is the standard of care in patients with advanced cervical cancer. However, a number of patients could not undergone brachytherapy due to massive residual tumor or anatomical distortion. In this study, we have evaluated the treatment outcome in patients with locally advanced cervical cancer, undergone conventional EBRT plus cisplatin based chemotherapy. METHODS: In this study, we have selected patients with locally advanced cervical carcinoma (stage: IIB to IIIB) undergone external beam radiotherapy and chemotherapy without brachytherapy at our institute between October of 2007 and October of 2009. The patients have received 50 Gy within 5 weeks to whole pelvic that has followed by a localized boost dose on tumor to 70 Gy concurrently with cisplatin 35 mg/m2 weekly. The treatment has related toxicities, and survival (overall and disease free) have evaluated. RESULTS: 30 cases with a median age of 55 (range; 40 to 73) have been studied. According to FIGO classification, the clinical stages were as follows: stage: IIB 23, IIIA 4, and IIIB 3 cases. Three months after treatment, 19 patients (63.3%) have achieved complete response. With a median follow up time of 18 months (range; 10-33 months), 8/23 cases (34.7%) with stage IIB and 2/7 (28.5%) among stage IIIA-IIIB remained disease free at the end of follow up. Data have shown a 2-year overall survival rate of 58.7% ± 9% and 2- year disease free survival of 37.7% ± 9% . Most toxicities were grade I and II. 2 (6.6%) grade III diarrhea and 4 (13.3%) grade III neutropenia have recorded. CONCLUSION: Although a considerable number of patients have achieved complete response using concurrent chemoradiotherapy without brachytherapy, the overall treatment outcomes especially for stage IIIA-IIIB were unsatisfactory. Using modern radiation therapy techniques with increased delivered boost dose could improve treatment results.
format Online
Article
Text
id pubmed-4142937
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Cancer Research Center, Shahid Beheshti University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-41429372014-09-23 Concurrent Chemoradiotherapy without Brachytherapy in Locally Advanced Cervical Cancer Kadkhodayan, Sima Homaei Shandiz, Fatemeh Seilanian Toussi, Mehdi Afzal Aghaee, Monavar Farshidi, Farnoosh Dehghan, Parvane Iran J Cancer Prev Clinical Trial BACKGROUND: Concurrent chemoradiotherapy (EBRT + cisplatin) plus intracavitary brachytherapy is the standard of care in patients with advanced cervical cancer. However, a number of patients could not undergone brachytherapy due to massive residual tumor or anatomical distortion. In this study, we have evaluated the treatment outcome in patients with locally advanced cervical cancer, undergone conventional EBRT plus cisplatin based chemotherapy. METHODS: In this study, we have selected patients with locally advanced cervical carcinoma (stage: IIB to IIIB) undergone external beam radiotherapy and chemotherapy without brachytherapy at our institute between October of 2007 and October of 2009. The patients have received 50 Gy within 5 weeks to whole pelvic that has followed by a localized boost dose on tumor to 70 Gy concurrently with cisplatin 35 mg/m2 weekly. The treatment has related toxicities, and survival (overall and disease free) have evaluated. RESULTS: 30 cases with a median age of 55 (range; 40 to 73) have been studied. According to FIGO classification, the clinical stages were as follows: stage: IIB 23, IIIA 4, and IIIB 3 cases. Three months after treatment, 19 patients (63.3%) have achieved complete response. With a median follow up time of 18 months (range; 10-33 months), 8/23 cases (34.7%) with stage IIB and 2/7 (28.5%) among stage IIIA-IIIB remained disease free at the end of follow up. Data have shown a 2-year overall survival rate of 58.7% ± 9% and 2- year disease free survival of 37.7% ± 9% . Most toxicities were grade I and II. 2 (6.6%) grade III diarrhea and 4 (13.3%) grade III neutropenia have recorded. CONCLUSION: Although a considerable number of patients have achieved complete response using concurrent chemoradiotherapy without brachytherapy, the overall treatment outcomes especially for stage IIIA-IIIB were unsatisfactory. Using modern radiation therapy techniques with increased delivered boost dose could improve treatment results. Cancer Research Center, Shahid Beheshti University of Medical Sciences 2013 /pmc/articles/PMC4142937/ /pubmed/25250134 Text en © 2014 Cancer Research Center, Shahid Beheshti University of Medical Sciences http://creativecommons.org/licenses/by-nc/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
spellingShingle Clinical Trial
Kadkhodayan, Sima
Homaei Shandiz, Fatemeh
Seilanian Toussi, Mehdi
Afzal Aghaee, Monavar
Farshidi, Farnoosh
Dehghan, Parvane
Concurrent Chemoradiotherapy without Brachytherapy in Locally Advanced Cervical Cancer
title Concurrent Chemoradiotherapy without Brachytherapy in Locally Advanced Cervical Cancer
title_full Concurrent Chemoradiotherapy without Brachytherapy in Locally Advanced Cervical Cancer
title_fullStr Concurrent Chemoradiotherapy without Brachytherapy in Locally Advanced Cervical Cancer
title_full_unstemmed Concurrent Chemoradiotherapy without Brachytherapy in Locally Advanced Cervical Cancer
title_short Concurrent Chemoradiotherapy without Brachytherapy in Locally Advanced Cervical Cancer
title_sort concurrent chemoradiotherapy without brachytherapy in locally advanced cervical cancer
topic Clinical Trial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4142937/
https://www.ncbi.nlm.nih.gov/pubmed/25250134
work_keys_str_mv AT kadkhodayansima concurrentchemoradiotherapywithoutbrachytherapyinlocallyadvancedcervicalcancer
AT homaeishandizfatemeh concurrentchemoradiotherapywithoutbrachytherapyinlocallyadvancedcervicalcancer
AT seilaniantoussimehdi concurrentchemoradiotherapywithoutbrachytherapyinlocallyadvancedcervicalcancer
AT afzalaghaeemonavar concurrentchemoradiotherapywithoutbrachytherapyinlocallyadvancedcervicalcancer
AT farshidifarnoosh concurrentchemoradiotherapywithoutbrachytherapyinlocallyadvancedcervicalcancer
AT dehghanparvane concurrentchemoradiotherapywithoutbrachytherapyinlocallyadvancedcervicalcancer